RNS Number : 4819E
Oxford Cannabinoid Tech.Holdings
26 February 2024
 

Oxford Cannabinoid Technologies Holdings plc

("OCT" or the "Company")

 

Directors' Dealings

 

Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), the biotech company developing prescription cannabinoid medicines, announces that it has been informed that Clarissa Sowemimo-Coker, the Chief Executive Officer of the Company, and Julie Pomeroy, the Company's Non-Executive Chair, have today purchased ordinary shares of ÂŁ0.001 ("Ordinary Shares") in the Company.

 

Director

Total number of Ordinary Shares purchased

Price per Ordinary Share

Number of Ordinary Shares held following the purchase

Clarissa Sowemimo-Coker

1,000,000

ÂŁ0.0045

2,500,000

Julie Pomeroy

450,000

ÂŁ0.004575

650,000

 

Clarissa Sowemimo-Coker, Chief Executive Officer of OCT, said:

 

"Today marks further evidence of the management's support of OCT, following our participation in a successful fundraise in January 2024 where we also welcomed Cantheon Capital LLC as a cornerstone investor of the Company. Both I and OCT's chair, Julie Pomeroy, have increased our personal shareholdings in OCT, demonstrating our commitment to the business and our resolute belief in the Company's future pipeline. I look forward to continuing to work with colleagues to deliver further for our shareholders with the ultimate aim of helping people living with debilitating conditions."

 

The PDMR forms are set out below.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

The Directors of the Company take responsibility for this announcement.

 

Enquiries:

 

Oxford Cannabinoid Technologies Holdings plc

+44 (0)20 3034 2820

Clarissa Sowemimo-Coker (CEO)

clarissa@oxcantech.com



Cairn Financial Advisers LLP


Emily Staples

+44 (0)20 7213 0897

Jo Turner

+44 (0) 20 7213 0885



Axis Capital Markets Limited


Richard Hutchison

+44 (0)20 3026 0320



Acuitas Communications

020 3745 0293 / 07799 767676

Simon Nayyar

simon.nayyar@acuitascomms.com

Arthur Dingemans

arthur.dingemans@acuitascomms.com

 

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCT") is the holding company of Oxford Cannabinoid Technologies Ltd and OCT Victoria Pty Ltd (together the "Group"), a pharmaceutical Group developing prescription cannabinoid medicines initially targeting the US$ multi-billion global pain market.

 

OCT currently has a portfolio of four drug development programmes. Its lead compound, OCT461201, will initially target neuropathic and visceral pain (including irritable bowel syndrome ("IBS") and chemotherapy induced peripheral neuropathy ("CIPN"). The global market for CIPN alone is currently forecast to reach US$1.17bn by 2028.

 

OCT's drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. Having established an exclusive licence agreement with Canopy Growth Corporation for their entire pharmaceutical cannabinoid derivative library, OCT now has a portfolio of almost five hundred derivatives and intellectual property rights including fourteen patent families and associated research data.

 

OCT has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCT's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Clarissa Sowemimo-Coker

2

Reason for notification

 

 

 

a.

Position/Status

Chief Executive Officer

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Oxford Cannabinoid Technologies Holdings plc

b.

LEI

           

2138005SRWT4998BCE35

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

 

Ordinary shares of ÂŁ0.001 each

 

 

GB00BMVMRB86

b.

Nature of the transaction

Acquisition of ordinary shares of ÂŁ0.001 each

c.

Price(s) and volume(s)







Price(s)

Volume(s)


ÂŁ0.0045

1,000,000



d.

Aggregated information

 

- Aggregated Volume

 

- Price

N/A - Single Transaction

e.

Date of the transaction

26 February 2024

f.

Place of the transaction

London, UK

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Julie Pomeroy

2

Reason for notification

 

 

 

a.

Position/Status

Non-Executive Chair

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Oxford Cannabinoid Technologies Holdings plc

b.

LEI

           

2138005SRWT4998BCE35

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

 

Ordinary shares of ÂŁ0.001 each

 

 

GB00BMVMRB86

b.

Nature of the transaction

Acquisition of ordinary shares of ÂŁ0.001 each

c.

Price(s) and volume(s)







Price(s)

Volume(s)


ÂŁ0.004575

450,000



d.

Aggregated information

 

- Aggregated Volume

 

- Price

N/A - Single Transaction

e.

Date of the transaction

26 February 2024

f.

Place of the transaction

London, UK

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGZGZZFVDGDZM
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Oxford Cannabinoid Techn... Charts.
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Oxford Cannabinoid Techn... Charts.